Milademetan achieved a confirmed ORR of 3.2% (with unconfirmed responses up to 19.4%), whereas Alrizomadlin demonstrated an ORR of 25% specifically in MDM2-amplified, TP53-wild-type solid tumors, with some patients experiencing delayed tumor regression consistent with immunomodulatory activity [26]. Here, MDM2 is linked to neoplasm.